Use of hydroxy‐methyl‐glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies

It has been speculated that the use of hydroxy‐methyl‐glutaryl coenzyme A reductase inhibitors (statins) is associated with the risk of malignant diseases. Considering their immunosuppressive activities, malignant diseases that are associated with an immunosuppressive status seem feasible to examine...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer science 2006-02, Vol.97 (2), p.133-138
Hauptverfasser:	Iwata, Hiroshi, Matsuo, Keitaro, Hara, Shigeo, Takeuchi, Kengo, Aoyama, Tomonori, Murashige, Naoko, Kanda, Yoshinobu, Mori, Shin‐ichiro, Suzuki, Risturo, Tachibana, Shintaro, Yamane, Masaaki, Odawara, Masato, Mutou, Yoshitomo, Kami, Masahiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Aged Aged, 80 and over Antigens Biological and medical sciences Carcinogenicity Case-Control Studies Cholesterol Coenzyme A Drug dosages Fatty Acids, Monounsaturated - therapeutic use Female Fluvastatin Hematologic and hematopoietic diseases Hematology Hepatitis Hospitals Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Immunoglobulins Indoles - therapeutic use Japan - epidemiology Leukemia Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma Lymphoma - epidemiology Lymphoma - pathology Male Malignancy Medical records Medical sciences Mortality Multiple myeloma Multiple Myeloma - epidemiology Multiple Myeloma - pathology Myeloma Original Orthopedics Otolaryngology Patients Pravastatin - therapeutic use Reductase Risk Factors Simvastatin - therapeutic use Statins Tumors
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!